title: Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.
abstract: Two techniques employed for the early diagnosis of dementia are the imaging of amyloid-beta protein using positron emission tomography (PET) and voxel-based morphometry analysis of MRI (VBM-MRI). The purpose of this study was to evaluate the clinical utility of amyloid PET and VBM-MRI for the early diagnosis and tracking of the severity of Alzheimer's disease (AD). The neuritic plaque burden and gray matter losses were evaluated using [11C]BF-227-PET and VBM-MRI in 12 healthy controls, 13 subjects with mild cognitive impairment (MCI), including 6 who converted to AD and 7 who did not convert, and 15 AD patients. The AD patients and the MCI converters exhibited a neocortical retention of BF-227 and parahippocampal gray matter loss shown by VBM-MRI. The MCI converters were more clearly distinguished from the MCI non-converters in BF-227-PET than VBM-MRI. The combined sample of the MCI converters and AD patients showed a significant correlation of MMSE scores with the global gray matter loss, but not with the BF-227 retention. These findings suggest that amyloid PET using [11C]BF-227 is better suited for the prediction of conversion from MCI to AD, while VBM-MRI appears to be better suited for tracking the severity of dementia.
authors: Department of Geriatrics and Gerontology, Division of Brain Sciences, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
authors: Masaaki
authors: M
authors: Waragai
authors: Nobuyuki
authors: N
authors: Okamura
authors: Katsutoshi
authors: K
authors: Furukawa
authors: Manabu
authors: M
authors: Tashiro
authors: Shozo
authors: S
authors: Furumoto
authors: Yoshihito
authors: Y
authors: Funaki
authors: Motohisa
authors: M
authors: Kato
authors: Ren
authors: R
authors: Iwata
authors: Kazuhiko
authors: K
authors: Yanai
authors: Yukitsuka
authors: Y
authors: Kudo
authors: Hiroyuki
authors: H
authors: Arai
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D001583:Benzoxazoles; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D002250:Carbon Radioisotopes; D003072:Cognition Disorders / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D042241:Early Diagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D019579:Neocortex / Q000000981:diagnostic imaging / Q000473:pathology; D036421:Nerve Fibers, Unmyelinated / Q000473:pathology; D009483:Neuropsychological Tests; D020534:Parahippocampal Gyrus / Q000000981:diagnostic imaging / Q000473:pathology; D058225:Plaque, Amyloid / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D012720:Severity of Illness Index; D012815:Signal Processing, Computer-Assisted; D013844:Thiazoles
chemical_list: C516779:2-(2-(2-dimethylaminothiazol-5-yl)ethenyl)-6-(2-(fluoro)ethoxy)benzoxazole; D001583:Benzoxazoles; D002250:Carbon Radioisotopes; D013844:Thiazoles